![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
SVR Reduces Morbidity/Deaths by 5-10 Fold - Abbvie Analysis - Percent of Subjects Experiencing Liver Morbidity Over a Lifetime Horizon with AbbVie 3D (Abt-450/Ritonavir/Ombitasvirand Dasabuvir) Versus No treatment
|
|
|
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
SJ Johnson1, H Parise1, S Virabhak1, tR Juday2, JC Samp2, SE Marx2, S Saab3
1Medicus Economics, Milton; 2Global Health Economics and Outcomes Research, AbbVie, Mettawa; 3Pfleger Liver Institute, Los Angeles, United States
EASL: The Value of Survival Benefits from Treating Hepatitis C at Different Fibrosis Stages with All-Oral, Interferon-Free Therapy Relative to 'Watchful Waiting' - (04/28/15)
EASL: Reduction in Annual Medical Costs with Early Treatment of HCV Using Abbvie 3D (AbT-450/Ritonavir/Ombitasvir and Dasabuvir) ± Ribavirin in the United States - (04/28/15)
EASL: Healthcare Costs by Stage of Liver Disease in Chronic Hepatitis C Patients in the United States - (04/27/15)
![EASL1.gif](../images/043115/043115-8/EASL1.gif)
![EASL2.gif](../images/043115/043115-8/EASL2.gif)
![EASL3.gif](../images/043115/043115-8/EASL3.gif)
![EASL4.gif](../images/043115/043115-8/EASL4.gif)
![EASL5.gif](../images/043115/043115-8/EASL5.gif)
![EASL6.gif](../images/043115/043115-8/EASL6.gif)
![EASL7.gif](../images/043115/043115-8/EASL7.gif)
![EASL8.gif](../images/043115/043115-8/EASL8.gif)
![EASL9.gif](../images/043115/043115-8/EASL9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|